IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer
Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.
Related Articles
EBC-129 Receives FDA Fast-Track Designation for PDAC
Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.
Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025
Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.
Camrelizumab/Apatinib Plus Chemotherapy May Show Promise in ES-SCLC
The safety profile of camrelizumab plus apatinib and chemotherapy in a phase 1 study aligns with prior reports of each agent.
Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC
Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.
Identifying the Treatment Landscape for Advanced Lung Cancers
Thoracic surgeon Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
Episode 5: Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer
Panelists discuss how the evolving landscape of adjuvant therapy in kidney cancer, including targeted therapies and immunotherapy like pembrolizumab, offers curative potential for high-risk patients,…
Sacituzumab Govitecan Improves PFS in 1L PD-1/PD-L1 Inhibitor Ineligible mTNBC
In the phase 3 ASCENT-03 trial, sacituzumab govitecan did not show an OS detriment vs chemotherapy in previously untreated metastatic triple-negative breast cancer.
CHMP Recommends Approval of Belantamab Mafodotin Combos in Multiple Myeloma
The European Commission is expected to approve the belantamab mafodotin combinations for this multiple myeloma population in the third quarter of 2025.
Avutometinib/Defactinib Combo May Elicit Efficacy in Metastatic PDAC
Ten of 12 patients with metastatic pancreatic ductal adenocarcinoma given the recommended phase 2 dose of the combination regimen had a response.
ONCOLOGY Vol 39, Issue 4
CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.